myasthenia gravis/tyrosine

پیوند در کلیپ بورد ذخیره می شود

نوع مرتب سازی را انتخاب کنید

صفحه 1 از جانب 280 نتایج

Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

OBJECTIVE Important concepts regarding the pathogenesis, clinical features, diagnosis and treatment of muscle-specific tyrosine kinase (MuSK) antibody positive myasthenia gravis will be reviewed. Special attention will be paid to clinical phenotypes and treatment, particularly encouraging responses

Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Antibodies to muscle-specific receptor tyrosine kinase (MuSK-Ab) are detected in approximately 40% of generalized acetylcholine receptor (AChR) antibody-negative myasthenia gravis (MG). Based on a growing number of clinical series, a MuSK-Ab-positive phenotype is emerging. While these clinical

Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Muscle-specific tyrosine-kinase-antibody-positive myasthenia gravis (MuSK-MG) has emerged as a distinct entity since 2001. This disease has been reported worldwide, but with varying rates among patients with generalized acetylcholine-receptor-antibody-negative MG. MuSK-MG was detected in

Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Autoimmune myasthenia gravis is usually characterized by the presence of autoantibodies against the acetylcholine receptor (~80-90% of patients) or muscle-specific tyrosine kinase (MuSK) (~5% of patients). In the remaining patients, no such antibodies (Abs) are detectable, but this could be due

A misdiagnosed myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies with possible childhood onset.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

BACKGROUND Childhood onset myasthenia gravis associated with anti-muscle-specific tyrosine kinase antibodies is very rare and atypical in presentation. METHODS As a baby, the pre- sented patient was choking and sleeping with open eyes. She had weak cry and breathing difficulties. In childhood, there

Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG characterized by more frequent relapses and a clinical course that is refractory to standard treatments. Rituximab, a monoclonal antibody targeting CD20+ B cells, has been used effectively in

Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Myasthenia gravis (MG) and its murine model experimental autoimmune myasthenia gravis (EAMG) are T cell-dependent, antibody-mediated autoimmune diseases. Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1) is a cytosolic tyrosine phosphatase that is involved in regulating the T

Muscle atrophy in muscle-specific tyrosine kinase (MuSK)-related myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibody (MuSK-MG) is often associated with prominent facial and bulbar muscle atrophy. It remains unclear whether the muscle atrophy is a consequence of long-term corticosteroid treatment, or of the disease process per se. Herein,

Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Background: The onset of myasthenia (MG) gravis with anti-muscle-specific tyrosine kinase (MuSK) antibodies most commonly peaks in the fourth decade of life, and MG with MuSK antibodies (MuSK-MG) rarely coexists with a malignant tumor. To

Myasthenia Gravis with Anti-Muscle-Specific Tyrosine Kinase Antibody during Pregnancy and Risk of Neonatal Myasthenia Gravis: A Case Report and Review of the Literature.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

A 31-year-old woman presented with a nasal voice, dysarthria, and upper limb weakness during her first pregnancy. Soon after delivery of her first baby, her symptoms disappeared. At the age of 34 years, during her second pregnancy, her nasal voice re-appeared. After delivery of the second baby, her

High frequency of DQB105 and absolute absence of DRB113 in muscle-specific tyrosine kinase positive myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

OBJECTIVE Myasthenia gravis (MG) is an autoimmune disease but certain genetic factors predispose its development. Since susceptibility to different forms of MG is linked to a number of allelic variants, the aim of this study was to explore the human leukocyte antigen (HLA) profile of our patients

Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

The use of cyclophosphamide and rituximab for patients with refractory myasthenia gravis has shown promising results. We report on a 31-year-old Chinese woman with acetylcholine receptor antibody-negative and muscle-specific tyrosine kinase antibody-positive generalised myasthenia gravis who had

Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Approximately 10%-15% of patients with myasthenia gravis (MG) are refractory to standard treatment. A sizable chunk of these patients is due to muscle-specific tyrosine kinase (MuSK) antibody-positive MG which often runs a severe course with frequent relapses and poor response to

Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Muscle-specific tyrosine kinase (MuSK) antibodies are detected in a proportion of myasthenia gravis (MG) patients who are negative for acetylcholine receptor (AChR) antibodies and have prominent bulbar weakness and crises. In the MuSK ectodomains, the immunoglobulin-like 1 and 2 domains (Ig1/2)

Management challenges in muscle-specific tyrosine kinase myasthenia gravis.

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند

ورود به سیستم / ثبت نام

Myasthenia gravis with antibodies to muscle-specific tyrosine kinase (MuSK-MG) is generally considered a severe disease because of the associated weakness distribution with prevalent involvement of bulbar muscles and a rapidly progressive course and early respiratory crises. Its treatment can be

قبلی
1
2
3
4
5
6
...
18
19
بعد

به صفحه فیس بوک ما بپیوندید

Herbal & Natural Medicine

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی

به 55 زبان کار می کند
درمان های گیاهی با پشتوانه علم
شناسایی گیاهان توسط تصویر
نقشه GPS تعاملی - گیاهان را در مکان نشان دهید (به زودی)
انتشارات علمی مربوط به جستجوی خود را بخوانید
گیاهان دارویی را با توجه به اثرات آنها جستجو کنید
علایق خود را سازماندهی کنید و با تحقیقات اخبار ، آزمایشات بالینی و حق ثبت اختراع در جریان باشید

علامت یا بیماری را تایپ کنید و در مورد گیاهانی که ممکن است به شما کمک کنند ، بخوانید ، یک گیاه تایپ کنید و بیماری ها و علائمی را که در برابر آن استفاده می شود ، ببینید.
* کلیه اطلاعات براساس تحقیقات علمی منتشر شده است

myasthenia gravis/tyrosine

Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis.

Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis.

Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis.

A misdiagnosed myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies with possible childhood onset.

Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.

Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.

Muscle atrophy in muscle-specific tyrosine kinase (MuSK)-related myasthenia gravis.

Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report

Myasthenia Gravis with Anti-Muscle-Specific Tyrosine Kinase Antibody during Pregnancy and Risk of Neonatal Myasthenia Gravis: A Case Report and Review of the Literature.

High frequency of DQB1*05 and absolute absence of DRB1*13 in muscle-specific tyrosine kinase positive myasthenia gravis.

Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.

Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.

Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis.

Management challenges in muscle-specific tyrosine kinase myasthenia gravis.

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی

High frequency of DQB105 and absolute absence of DRB113 in muscle-specific tyrosine kinase positive myasthenia gravis.